Barinthus Biotherapeutics (BRNS) Short Interest Ratio & Short Volume

Short interest is the volume of Barinthus Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 41,600 shares of BRNS short. 0.11% of Barinthus Biotherapeutics' shares are currently sold short. Learn More on Barinthus Biotherapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.11% of Barinthus Biotherapeutics' floating shares are currently sold short.

Barinthus Biotherapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 41,600 shares, an increase of 36.8% from the previous total of 30,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Barinthus Biotherapeutics currently has issued a total of 40,340,000 shares. Some of Barinthus Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Barinthus Biotherapeutics currently has a public float of 36,930,000 shares.

0.11% of Barinthus Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Barinthus Biotherapeutics: China SXT Pharmaceuticals, Inc. (0.07%), Journey Medical Corporation (13.91%), Semper Paratus Acquisition Corporation (4.86%), Aclaris Therapeutics, Inc. (6.40%), Lifevantage Corporation (23.30%), C4 Therapeutics, Inc. (7.17%), Voyager Therapeutics, Inc. (6.18%), Greenwich LifeSciences, Inc. (17.36%), Contineum Therapeutics, Inc. (1.97%), Lyell Immunopharma, Inc. (3.29%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), MicroStrategy Incorporated ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks.

Short selling BRNS is an investing strategy that aims to generate trading profit from Barinthus Biotherapeutics as its price is falling. BRNS shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Barinthus Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BRNS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BRNS, twice per month. The most recent reporting period available is July, 31 2025.